What are the major opportunities in the B-Cell Maturation Antigen (BCMA) Targeted Therapies market? What are the strategies for the B-Cell Maturation Antigen (BCMA) Targeted Therapies market?

For detailed insights on the major opportunities and strategies in the B-Cell Maturation Antigen (BCMA) Targeted Therapies market, Read More

How does the B-Cell Maturation Antigen (BCMA) Targeted Therapies market relate to the overall economy and other similar markets?

For detailed insights on B-Cell Maturation Antigen (BCMA) Targeted Therapies's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the B-Cell Maturation Antigen (BCMA) Targeted Therapies market growth? SWOT analysis of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market.

For detailed insights on the key dynamics influencing the B-Cell Maturation Antigen (BCMA) Targeted Therapies market growth and SWOT analysis of the B-Cell Maturation Antigen (BCMA) Targeted Therapies industry, Read More

Global B Cell Maturation Antigen BCMA Targeted Therapies Market Report 2025

Item added to cart!

Published : December 2025

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report 2025

Name: B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Product Type (Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies), By Indication Type (Acute Lymphoblastic Leukemia, Multiple Myeloma), By End User (Hospitals, Specialty Clinics, Home Care Settings) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

• B-Cell Maturation Antigen (BCMA) Targeted Therapies market size has reached to $12.17 billion in 2024

• Expected to grow to $35.81 billion in 2029 at a compound annual growth rate (CAGR) of 24.1%

• Growth Driver: Rising Incidence Of Multiple Myeloma

• Market Trend: Innovations in CAR-T Cell Treatment for Multiple Myeloma

• North America was the largest region in 2024.

What Is Covered Under B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

B-cell maturation antigen (BCMA) targeted therapies refer to a class of treatments designed to specifically target BCMA, a protein expressed on the surface of mature B-cells and plasma cells. BCMA is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in B-cell development, survival, and differentiation into plasma cells. BCMA-targeted therapies represent a significant advancement in the treatment of multiple myeloma, offering effective options for patients with relapsed or refractory disease.

The main types of products for B-cell maturation antigen (BCMA) targeted therapies include antibody-drug conjugates (ADCs), chimeric antigen receptor T (CAR-T) cell therapy, and bispecific antibodies. antibody drug conjugates (ADCs) are targeted therapies that link a cancer-specific antibody to a cytotoxic drug, enabling precise destruction of cancer cells while minimizing damage to healthy tissue. Main types of indication type are acute lymphoblastic leukemia, and multiple myeloma and used by various end users including hospitals, specialty clinics, and home care settings.

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and growth rate 2025 to 2029: Graph

What Is The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025 And Growth Rate?

The B-cell maturation antigen (BCMA) targeted therapies market size has grown exponentially in recent years. It will grow from $12.17 billion in 2024 to $15.09 billion in 2025 at a compound annual growth rate (CAGR) of 24.0%. The growth in the historic period can be attributed to growing focus on hematologic malignancies, rising investments in oncology research, growing demand for personalized medicine, increasing adoption of CAR-T cell therapies, and rising healthcare expenditure.

What Is The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Forecast?

The B-cell maturation antigen (BCMA) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $35.81 billion in 2029 at a compound annual growth rate (CAGR) of 24.1%. The growth in the forecast period can be attributed to growing focus on cancer research, shifts toward targeting specific molecular markers, incidence of cancers, surge in biotech investments, and increasing use of cell and gene therapies. Major trends in the forecast period include innovations such as CRISPR technology, advancements in gene-editing technologies, advancements in the next-generation car-t cell therapies, advances in targeted antibody-drug conjugates, and development of off-the-shelf treatments.

The forecast of 24.1% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. myeloma treatment by inflating prices of Chimeric Antigen Receptor T-cell therapy(CAR-T) cell therapies and bispecific antibodies developed in Belgium and China, resulting in delayed access to breakthrough treatments and higher oncology center costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segmented?

1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies

2) By Indication Type: Acute Lymphoblastic Leukemia, Multiple Myeloma

3) By End User: Hospitals, Specialty Clinics, Home Care Settings

Subsegments:

1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs

2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells

3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies

What Is Driving The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market? Rising Incidence Of Multiple Myeloma

The rising incidence of multiple myeloma is expected to propel the growth of the b-cell maturation antigen (BCMA) targeted therapies market going forward. Multiple myeloma is a type of cancer that primarily affects plasma cells, which are a crucial component of the immune system responsible for producing antibodies. The increasing incidence of multiple myeloma is attributed to several factors, including an aging global population, improved diagnostic capabilities, and variations in healthcare access. B-cell maturation antigen (BCMA) targeted therapies are crucial in treating multiple myeloma by targeting and eliminating malignant plasma cells that express BCMA, offering a promising approach for more effective and targeted treatment. For instance, in August 2024, according to the American Cancer Society, a US-based professional organization, in 2024, approximately 35,780 new cases of multiple myeloma were diagnosed in the United States, with 19,520 cases in men and 16,260 cases in women. Additionally, about 12,540 deaths are anticipated, including 7,020 in men and 5,520 in women. Therefore, the rising incidence of multiple myeloma is driving growth in the b-cell maturation antigen (BCMA) targeted therapies industry.

Who Are The Major Players In The Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.

What Are The Key Trends Of The Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market? Innovations in CAR-T Cell Treatment for Multiple Myeloma

Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are focusing on developing innovative treatments such as CAR-T cell therapy to enhance the efficacy and precision of targeting cancer cells. CAR-T cell therapy is a type of immunotherapy that involves modifying a patient's T cells to express chimeric antigen receptors (CARs) to target and kill cancer cells. For instance, in April 2024, Johnson & Johnson, a US-based pharmaceutical industry company, received U.S. Food and Drug Administration (FDA) approval for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy for treating adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy and are refractory to lenalidomide.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market? Astrazeneca Acquires Gracell Biotechnologies Inc. To Expand Cell Therapy Portfolio

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical industry company, acquired Gracell Biotechnologies Inc. for approximately $1.2 billion. With this acquisition, AstraZeneca aims to enhance its cell therapy portfolio by integrating Gracell's FasTCAR-enabled GC012F therapy, targeting cancer and autoimmune diseases, to address significant unmet medical needs. Gracell Biotechnologies Inc. is a China-based biotechnology company specializing in developing B-cell maturation antigen (BCMA) therapies for multiple myeloma and B-cell malignancies.

What Is The Regional Outlook For The Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

The B-cell maturation antigen (BCMA) targeted therapies market consists of revenues earned by entities by providing services such as research and development services, clinical trials management, manufacturing and production services, regulatory consulting and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The B-cell maturation antigen (BCMA) targeted therapies market also includes sales of antibody-drug conjugates (ADCs), BCMA-targeted immunotherapies, and gene therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry?

The b-cell maturation antigen (bcma) targeted therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the b-cell maturation antigen (bcma) targeted therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$15.09 billion
Revenue Forecast In 2034	$35.81 billion
Growth Rate	CAGR of 24.1% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The B-cell maturation antigen (BCMA) targeted therapies market covered in this report is segmented – 1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies 2) By Indication Type: Acute Lymphoblastic Leukemia, Multiple Myeloma 3) By End User: Hospitals, Specialty Clinics, Home Care Settings Subsegments: 1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs 2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells 3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Characteristics

3. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends And Strategies

4. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Growth Analysis And Strategic Analysis Framework

5.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate Analysis

5.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Total Addressable Market (TAM)

6. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segmentation

6.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antibody Drug Conjugates

Chimeric Antigen Receptor T (CAR-T)-Cell Therapy

Bispecific Antibodies

6.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Acute Lymphoblastic Leukemia

Multiple Myeloma

6.3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Home Care Settings

6.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

BCMA-Targeted ADCs (Antibody-Drug Conjugates)

Linker-Payload Technology-Based BCMA ADCs

6.5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

BCMA CAR-T Cells (Autologous)

Allogeneic BCMA CAR-T Cells

6.6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

BCMA x CD3 Bispecific Antibodies

BCMA x CD28 Bispecific Antibodies

7. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Regional And Country Analysis

7.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

8.1. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

9.1. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

9.2. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

10.1. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

11.1. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

11.2. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

12.1. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

13.1. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

14.1. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

14.2. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

15.1. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

15.2. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

16.1. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

17.1. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

18.1. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

19.1. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

20.1. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

21.1. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

21.2. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

22.1. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

23.1. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

23.2. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

24.1. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

24.2. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

25.1. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

25.2. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

26.1. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

26.2. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

27.1. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

28.1. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

28.2. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

29.1. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

29.2. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Landscape And Company Profiles

30.1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Landscape

30.2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Company Profiles

30.2.1. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Novartis Overview, Products and Services, Strategy and Financial Analysis

30.2.3. GlaxoSmithKline (GSK) Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis

31. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Other Major And Innovative Companies

31.1. Regeneron Pharmaceuticals

31.2. Beigene

31.3. Arcellx Inc

31.4. Poseida Therapeutics

31.5. Legend Biotech Corporation

31.6. Cartesian Therapeutics

31.7. Juno Therapeutics

31.8. Sutro Biopharma Inc

31.9. CARsgen Therapeutics

31.10. Precision BioSciences

31.11. Eureka Therapeutics Inc

31.12. Cellectis

31.13. Teneobio Inc.

31.14. Janssen Pharmaceuticals Companies

31.15. Allogene Therapeutics

32. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

34. Recent Developments In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

35. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market High Potential Countries, Segments and Strategies

35.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2029 - Countries Offering Most New Opportunities

35.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2029 - Segments Offering Most New Opportunities

35.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Bristol Myers Squibb Company Financial Performance

Table 78: Novartis Financial Performance

Table 79: GlaxoSmithKline (GSK) Financial Performance

Table 80: Takeda Pharmaceutical Company Limited Financial Performance

Table 81: Amgen Inc Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Bristol Myers Squibb Company Financial Performance

Figure 78: Novartis Financial Performance

Figure 79: GlaxoSmithKline (GSK) Financial Performance

Figure 80: Takeda Pharmaceutical Company Limited Financial Performance

Figure 81: Amgen Inc Financial Performance

Emerging Trends and Growth Drivers in the Pediatric Dental Market Through 2029

Competitive and Market Trend Analysis of Pharmaceutical Cold Chain Packaging Industry Through 2029

Key Market Drivers, Trends, and Forecast for the Global Pharmaceutical Warehousing Industry

2025 Analysis: Opportunities and Risks in the Evolving Precision Genomic Testing Market

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Next-Generation Antibody Therapeutics Global Market Report 2025 – By Types Of Antibodies (Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types), By Therapeutic Area ...

Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2025 – By Drug Class (Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs), By Therapy (Targeted Therapy, Immunotherapy...

Preventive Vaccines Global Market Report 2025 - By Type (Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines), By Disease Ty...

Therapeutic BCG Vaccines Global Market Report 2025 – By Type (Therapy BCG, Immune BCG), By Demographics (Pediatrics, Adults), By End Use (Hospitals, Clinics, Other End Users ) – Impact of Tariff and Trade War on Market S...

Targeted Therapy Global Market Report 2025 – By Type (Small Molecule Medicines, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Breast Cancer, ...

Swine Vaccines Global Market Report 2025 – By Product( Attenuated Live Vaccines, Inactivated Vaccines, Subunit Vaccines, DNA (Deoxyribonucleic Acid) Vaccines, Recombinant Vaccines), By Disease( Viral Infections, Bacteria...

Dendritic Cell Cancer Vaccine Global Market Report 2025 – By Product (CreaVax, Sipuleucel-T (Provenge), Other Products), By Distribution Channel (Hospitals, Cancer Centers, Ambulatory Surgical Centers, Clinics), By Appli...

Frequently Asked Questions

What is the definition of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market?

How will the B-Cell Maturation Antigen (BCMA) Targeted Therapies market drivers and restraints affect the market dynamics? What forces will shape the B-Cell Maturation Antigen (BCMA) Targeted Therapies industry going forward?

The market major growth driver - Rising Incidence Of Multiple Myeloma. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market?

The b-cell maturation antigen (bcma) targeted therapies market size has grown exponentially in recent years. It will grow from $12.17 billion in 2024 to $15.09 billion in 2025 at a compound annual growth rate (CAGR) of 24.0%. The growth in the historic period can be attributed to growing focus on hematologic malignancies, rising investments in oncology research, growing demand for personalized medicine, increasing adoption of CAR-T cell therapies, and rising healthcare expenditure. The b-cell maturation antigen (bcma) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to " $35.81 billion in 2029 at a compound annual growth rate (CAGR) of 24.1%. The growth in the forecast period can be attributed to growing focus on cancer research, shifts toward targeting specific molecular markers, incidence of cancers, surge in biotech investments, and increasing use of cell and gene therapies. Major trends in the forecast period include innovations such as CRISPR technology, advancements in gene-editing technologies, advancements in the next-generation car-t cell therapies, advances in targeted antibody-drug conjugates, and development of off-the-shelf treatments. For further insights on this market, request a sample here

How is the B-Cell Maturation Antigen (BCMA) Targeted Therapies market segmented?

The b-cell maturation antigen (bcma) targeted therapiesmarket covered in this report is segmented –
1) By Product Type: Antibody Drug Conjugates; Chimeric Antigen Receptor T (CAR-T)-Cell Therapy; Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia; Multiple Myeloma
3) By End User: Hospitals; Specialty Clinics; Home Care Settings Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates); Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous); Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies; BCMA x CD28 Bispecific Antibodies For further insights on this market, request a sample here

Which region has the largest share of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market? What are the other regions covered in the report?

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the B-Cell Maturation Antigen (BCMA) Targeted Therapies market?

What are the key trends in the B-Cell Maturation Antigen (BCMA) Targeted Therapies market?

Major trends in this market include Innovations in CAR-T Cell Treatment for Multiple Myeloma. For further insights on this market, request a sample here.